Stifel raised the firm’s price target on Kura Oncology to $25 from $24 and keeps a Buy rating on the shares following the full presentation of updated ziftomenib R/R NPM1m AML data at the EHA meeting. The data confirm the highest phase 1 menin inhibitor CR rates and strong durability, says the analyst, who continues to like ziftomenib for the subsequent stages of AML development in first-line combinations and maintenance.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on KURA:
- Kura Oncology Announces Commencement of Public Offering of Common Stock and Pre-Funded Warrants
- Kura Oncology Presents Late-Breaking Clinical Data for Menin Inhibitor Ziftomenib at 2023 European Hematology Association (EHA) Congress
- Biotech Alert: Searches spiking for these stocks today
- Over 100% Upside: Analysts See an Appealing Entry Point in These 2 Small-Cap Stocks
- Kura Oncology Announces Late-Breaking Abstract Accepted for Oral Presentation at the 2023 European Hematology Association (EHA) Congress